MGNX Macrogenics Inc

Price (delayed)

$21.89

Market cap

$1.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.48

Enterprise value

$1.12B

Highlights
Macrogenics's equity has surged by 84% YoY and by 18% QoQ
The gross profit has soared by 58% YoY and by 3% from the previous quarter
MGNX's net income is up by 10% YoY but it is down by 5% QoQ

Key stats

What are the main financial stats of MGNX
Market
Shares outstanding
60.04M
Market cap
$1.31B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.51
Price to sales (P/S)
11.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.4
Earnings
Revenue
$108.08M
EBIT
-$136.29M
EBITDA
-$124.41M
Free cash flow
-$102.07M
Per share
EPS
-$2.48
Free cash flow per share
-$1.78
Book value per share
$6.23
Revenue per share
$1.89
TBVPS
$7.61
Balance sheet
Total assets
$435.45M
Total liabilities
$84.91M
Debt
$28.57M
Equity
$350.53M
Working capital
$321.68M
Liquidity
Debt to equity
0.08
Current ratio
7.06
Quick ratio
6.6
Net debt/EBITDA
1.53
Margins
EBITDA margin
-115.1%
Gross margin
100%
Net margin
-126.1%
Operating margin
-126.7%
Efficiency
Return on assets
-36%
Return on equity
-46%
Return on invested capital
-86%
Return on capital employed
-35.6%
Return on sales
-126.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MGNX stock price

How has the Macrogenics stock price performed over time
Intraday
1.39%
1 week
2.63%
1 month
-28.86%
1 year
-16.29%
YTD
-4.24%
QTD
-31.27%

Financial performance

How have Macrogenics's revenue and profit performed over time
Revenue
$108.08M
Gross profit
$108.07M
Operating income
-$136.91M
Net income
-$136.29M
Gross margin
100%
Net margin
-126.1%
The gross profit has soared by 58% YoY and by 3% from the previous quarter
The revenue has soared by 58% YoY and by 3.1% QoQ
Macrogenics's operating margin has surged by 51% YoY
MGNX's net margin is up by 43% year-on-year

Growth

What is Macrogenics's growth rate over time

Valuation

What is Macrogenics stock price valuation
P/E
N/A
P/B
3.51
P/S
11.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.4
The EPS has grown by 20% YoY
Macrogenics's equity has surged by 84% YoY and by 18% QoQ
The P/B is 28% below the last 4 quarters average of 4.9 but 10% above the 5-year quarterly average of 3.2
The revenue has soared by 58% YoY and by 3.1% QoQ
The price to sales (P/S) is 28% lower than the last 4 quarters average of 16.0 and 21% lower than the 5-year quarterly average of 14.7

Efficiency

How efficient is Macrogenics business performance
The ROS has grown by 43% YoY
MGNX's return on equity is up by 26% year-on-year and by 9% since the previous quarter
MGNX's ROA is up by 22% YoY and by 7% from the previous quarter
MGNX's ROIC is up by 2.9% YoY

Dividends

What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGNX.

Financial health

How did Macrogenics financials performed over time
The total assets has soared by 64% YoY and by 15% from the previous quarter
MGNX's current ratio is up by 43% year-on-year and by 14% since the previous quarter
MGNX's debt is 92% smaller than its equity
Macrogenics's equity has surged by 84% YoY and by 18% QoQ
The debt to equity has dropped by 50% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.